Horizon Pharma PLC Valuation
Based on Macroaxis valuation methodology, the firm cannot be evaluated at this time. Horizon Pharma PLC regular Real Value cannot be determined due to lack of data. The prevalent price of Horizon Pharma PLC is $0.0. Our model calculates the value of Horizon Pharma PLC from evaluating the firm fundamentals such as Current Valuation of 26.87 B, return on asset of 0.0444, and Return On Equity of 0.0854 as well as inspecting its technical indicators and probability of bankruptcy.
Horizon Pharma Total Value Analysis
Horizon Pharma PLC is currently estimated to have valuation of 26.87 B with market capitalization of 26.63 B, debt of 2.56 B, and cash on hands of 2.13 B. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Horizon Pharma fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
26.87 B | 26.63 B | 2.56 B | 2.13 B |
Horizon Pharma Investor Information
About 99.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 1.0. Horizon Pharma PLC had not issued any dividends in recent years. Based on the key measurements obtained from Horizon Pharma's financial statements, Horizon Pharma PLC is not in a good financial situation at the moment. It has a very high risk of going through financial straits in April.Horizon Pharma Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Horizon Pharma has an asset utilization ratio of 39.82 percent. This connotes that the Company is making $0.4 for each dollar of assets. An increasing asset utilization means that Horizon Pharma PLC is more efficient with each dollar of assets it utilizes for everyday operations.Horizon Pharma Ownership Allocation
The majority of Horizon Pharma PLC outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Horizon Pharma to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Horizon Pharma PLC. Please pay attention to any change in the institutional holdings of Horizon Pharma PLC as this could imply that something significant has changed or is about to change at the company. On August 14, 2024, Representative Greg Landsman of US Congress acquired under $15k worth of Horizon Pharma PLC's common stock.Horizon Pharma Profitability Analysis
The company reported the previous year's revenue of 3.63 B. Net Income was 521.48 M with profit before overhead, payroll, taxes, and interest of 2.8 B.Horizon Pharma Growth Indicators
Investing in growth stocks can be very risky. If the company such as Horizon Pharma does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 235.2 M | |
| Quarterly Earnings Growth Y O Y | 1.077 | |
| Forward Price Earnings | 21.7391 |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Horizon Stock
If you are still planning to invest in Horizon Pharma PLC check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Horizon Pharma's history and understand the potential risks before investing.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |